Inventor · disambiguated record
Christian Gege
Also filed as: GEGE CHRISTIAN
36 granted patents·26 pending applications·107 citations·filing 2004–2024
96Inventor score
Files withGILEAD SCIENCES INC9ALANTOS PHARM HOLDING7INNOVATIVE MOLECULES GMBH7IMMUNIC AG6JANSSEN PHARMACEUTICA NV5
Top patents by PatentIndex Score
62 records- 0196US9751874B2Hydroxy containing FXR (NR1H4) modulating compoundsGILEAD SCIENCES INC·Filed 2015·Granted Sep 5, 2017·35 cites·12 claims
- 0292US11278534B2Enantiomers of substituted thiazoles as antiviral compoundsINNOVATIVE MOLECULES GMBH·Filed 2018·Granted Mar 22, 2022·6 cites·19 claims
- 0391US11970484B2LXR modulators with bicyclic core moietyORSOBIO INC·Filed 2023·Granted Apr 30, 2024·2 cites·24 claims
- 0490US11739065B2FXR (NR1H4) modulating compoundsGILEAD SCIENCES INC·Filed 2021·Granted Aug 29, 2023·1 cites·17 claims
- 0589US10421730B2FXR (NR1H4) modulating compoundsGILEAD SCIENCES INC·Filed 2017·Granted Sep 24, 2019·3 cites·15 claims
- 0689US9938278B2FXR (NR1H4) modulating compoundsGILEAD SCIENCES INC·Filed 2015·Granted Apr 10, 2018·9 cites·12 claims
- 0788US9932332B2FXR (NR1H4) modulating compoundsGILEAD SCIENCES INC·Filed 2017·Granted Apr 3, 2018·7 cites·6 claims
- 0885US10590094B2Aminothiazole derivatives useful as antiviral agentsINNOVATIVE MOLECULES GMBH·Filed 2017·Granted Mar 17, 2020·6 cites·20 claims
- 0985US7691851B2Metalloprotease inhibitors containing a heterocyclic moietyALANTOS PHARM HOLDING·Filed 2008·Granted Apr 6, 2010·10 cites·9 claims
- 1082US12291523B2LXR modulators with bicyclic core moietyORSOBIO INC·Filed 2024·Granted May 6, 2025·0 cites·2 claims
- 1179US11247986B2FXR (NR1H4) modulating compoundsGILEAD SCIENCES INC·Filed 2019·Granted Feb 15, 2022·1 cites·6 claims
- 1279US10774054B2FXR (NR1H4) modulating compoundsGILEAD SCIENCES INC·Filed 2019·Granted Sep 15, 2020·1 cites·23 claims
- 1378US12358903B2FXR (NR1H4) modulating compoundsGILEAD SCIENCES INC·Filed 2022·Granted Jul 15, 2025·0 cites·7 claims
- 1477US11618747B2LXR modulators with bicyclic core moietyORSOBIO INC·Filed 2019·Granted Apr 4, 2023·2 cites·22 claims
- 1577US10329286B2FXR (NR1H4) modulating compoundsGILEAD SCIENCES INC·Filed 2017·Granted Jun 25, 2019·1 cites·7 claims
- 1677US9850236B2Trifluoromethyl alcohols as modulators of RORγtJANSSEN PHARMACEUTICA NV·Filed 2015·Granted Dec 26, 2017·2 cites·43 claims
- 1775US2024408068A1Helicase Primase Inhibitors For Treating Cancer In A Combination Therapy With Oncolytic VirusesINNOVATIVE MOLECULES GMBH·Filed 2024·Application pending·0 cites
- 1874US12295945B2Enantiomers of substituted thiazoles as antiviral compoundsINNOVATIVE MOLECULES GMBH·Filed 2022·Granted May 13, 2025·0 cites·10 claims
- 1974US7427610B22-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour actionSTERIX LTD·Filed 2004·Granted Sep 23, 2008·8 cites·21 claims
- 2072US8835441B2Heterobicyclic metalloprotease inhibitorsSTEENECK CHRISTOPH·Filed 2011·Granted Sep 16, 2014·3 cites·10 claims
- 2171US9458104B2Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor RORγPHENEX PHARMACEUTICALS AG·Filed 2013·Granted Oct 4, 2016·2 cites·23 claims
- 2270US7713966B2Heterobicyclic metalloprotease inhibitorsALANTOS PHARM HOLDING·Filed 2007·Granted May 11, 2010·1 cites·12 claims
- 2369US7795245B2Heterobicyclic metalloprotease inhibitorsATLANTOS PHARMACEUTICALS HOLDI·Filed 2007·Granted Sep 14, 2010·2 cites·15 claims
- 2469US7419972B22-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1SCHERING AG·Filed 2005·Granted Sep 2, 2008·2 cites·26 claims
- 2566US9815851B2Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseasesPHENEX PHARMACEUTICALS AG·Filed 2012·Granted Nov 14, 2017·1 cites·22 claims
- 2665US7749996B2Heterotricyclic metalloprotease inhibitorsALANTOS PHARMACEUTICAL HOLDING·Filed 2007·Granted Jul 6, 2010·1 cites·14 claims
- 2764US2010087420A1Heterotricyclic Metalloprotease InhibitorsALANTOS PHARM HOLDING·Filed 2009·Application pending·0 cites
- 2863US2024335405A1Vidofludimus and related structures acting as nurr1 agonistsIMMUNIC AG·Filed 2024·Application pending·0 cites
- 2962US7244762B2Antitumoral d-homoestra-1,3,5 (10)-trien-3-yl 2-substituted sulfamatesSTERIX LTD·Filed 2004·Granted Jul 17, 2007·1 cites·24 claims
- 3062US2025243190A1New deuterated rorgamma/rorgammat inverse agonistsIMMUNIC AG·Filed 2023·Application pending·0 cites
- 3161US2009312312A1Heterobicyclic Metalloprotease InhibitorsALANTOS PHARM HOLDING·Filed 2009·Application pending·0 cites
- 3260US7732493B22-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1BAYER SCHERING PHARMA AG·Filed 2008·Granted Jun 8, 2010·0 cites·13 claims
- 3360US2025066290A1Dhodh inhibitors containing a carboxylic acid bioisostereIMMUNIC AG·Filed 2022·Application pending·0 cites
- 3460US2025032527A1Medical use of n4-hydroxy citicoline compoundsIMMUNIC AG·Filed 2022·Application pending·0 cites
- 3560US2021401810A1Helicase Primase Inhibitors For Treating Cancer In A Combination Therapy With Oncolytic VirusesINNOVATIVE MOLECULES GMBH·Filed 2019·Application pending·0 cites
- 3658US2024368145A1Methods for treating cancerIMMUNIC AG·Filed 2022·Application pending·0 cites
- 3757US2024199535A1Deuterated dhodh inhibitorsIMMUNIC AG·Filed 2022·Application pending·0 cites
- 3856US2007155738A1Heterobicyclic metalloprotease inhibitorsALANTOS PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 3955US8492570B22-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumor actionHILLISCH ALEXANDER·Filed 2008·Granted Jul 23, 2013·0 cites·5 claims
- 4054US10150762B2Trifluoromethyl alcohols as modulators of RORγtJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Dec 11, 2018·0 cites·15 claims
- 4154US2020148652A1Aminothiazole Derivatives Useful As Antiviral AgentsINNOVATIVE MOLECULES GMBH·Filed 2020·Application pending·0 cites
- 4252US2008161300A1Heterobicyclic metalloprotease inhibitorsALANTOS PHARM HOLDING·Filed 2007·Application pending·0 cites
- 4352US2025115565A1Solid crystalline forms of helicase-primase inhibitors and process of preparation thereofINNOVATIVE MOLECULES GMBH·Filed 2023·Application pending·0 cites
- 4452US2008221092A1Heterobicyclic metalloprotease inhibitorsBLUHM HARALD·Filed 2007·Application pending·0 cites
- 4551USRE42132EAntitumoral D-homoestra-1,3,5(10)-trien-3-yl 2-substituted sulfamatesSTERIX LTD·Filed 2004·Granted Feb 8, 2011·0 cites·25 claims
- 4651US2008221083A1Heterobicyclic metalloprotease inhibitorsHOCHGURTEL MATTHIAS·Filed 2007·Application pending·0 cites
- 4750US10080744B2Thiazoles as modulators of RORγtJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Sep 25, 2018·0 cites·26 claims
- 4850US7435757B22-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1SCHERING AG·Filed 2005·Granted Oct 14, 2008·0 cites·13 claims
- 4948US2010249102A1Heterotricyclic Metalloprotease InhibitorsALANTOS PHARM HOLDING·Filed 2010·Application pending·0 cites
- 5045US2006293345A1Heterobicyclic metalloprotease inhibitorsSTEENECK CHRISTOPH·Filed 2006·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Christian Gege files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →